Skip to main content
S&P 5007,611.17+0.34%DOW52,063.88-0.06%NASDAQ26,159.66+0.69%BTC$75,775.00-0.86%ETH$2,395.33-1.15%GOLD$4,393.00+1.39%OIL$102.24-3.39%
Smart Investors Daily
Ocular Therapeutix, Inc. logo

NASDAQ · OCUL

Ocular Therapeutix, Inc.

Healthcare · Biotechnology

$10.19

Up+$0.02 (+0.15%)

Updated Sep 16, 2026, 3:21 PM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.55B
P/E ratio
-10.81
Dividend yield
0.00%
52-week range
$7.38 – $11.74
Volume
2.1M
Avg. volume
3.15M

Price performance

OCUL price history

1M range · 20 trading sessions · Daily adjusted prices

OCUL closed at $10.19 after 20 trading sessions, down 7.45% for the selected period.

Last close
$10.19
Period change
-7.45%
Period low
$10.19
Period high
$11.73
Daily close
View OHLC price history
OCUL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$10.795$10.89$10.13$10.192.1M
Sep 14, 2026$10.61$10.85$10.4906$10.721.62M
Sep 11, 2026$10.75$10.94$10.365$10.492.64M
Sep 10, 2026$11.43$11.43$10.535$10.622.39M
Sep 9, 2026$11.24$11.48$11.02$11.472.8M
Sep 8, 2026$10.56$11.44$10.40$11.372.74M
Sep 4, 2026$10.51$10.77$10.51$10.641.31M
Sep 3, 2026$10.98$11.08$10.415$10.642.13M
Sep 2, 2026$10.58$11.01$10.47$10.902.07M
Sep 1, 2026$10.42$10.66$10.32$10.571.58M
Aug 31, 2026$10.30$10.535$10.13$10.491.52M
Aug 28, 2026$10.97$10.97$10.33$10.361.56M
Aug 27, 2026$10.63$10.955$10.57$10.821.43M
Aug 26, 2026$10.79$10.905$10.685$10.771.37M
Aug 25, 2026$10.98$11.17$10.87$10.881.84M
Aug 24, 2026$11.03$11.05$10.61$10.782.36M
Aug 21, 2026$11.10$11.49$10.935$11.083.05M
Aug 20, 2026$11.525$11.619$11.07$11.093.29M
Aug 19, 2026$11.29$11.74$11.185$11.733.02M
Aug 18, 2026$10.50$11.215$10.3015$11.014.58M

Latest OCUL news

The latest Smart Investors Daily articles mentioning OCUL.

Stock researchCompany · Overview

OCUL research

Overview

Company profile and research snapshot.

Company profile

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$26.25
Implied upside
—
Analysts
—
OCUL recent ratings
DateFirmRatingTarget
Aug 4, 2026Chardan CapitalBuy—
Jun 25, 2026Chardan CapitalBuy—
Jun 18, 2026HC Wainwright & Co.Buy—
Jun 18, 2026BairdOutperform—
May 6, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 24, 2026

Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?

Ocular Therapeutix (OCUL) has drawn investor attention after recent trading saw the stock close at $8.62, with returns under pressure over the past month and past 3 months despite positive annual revenue growth. See our latest analysis for Ocular Therapeutix. Over a longer horizon, Ocular Therapeutix’s share price has come under pressure, with the year to date share price return down 27.07%, while the 3 year total shareholder return is up 100%. This points to strong historical swings in...

Yahoo · Jul 23, 2026

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Drug Administration on

Yahoo · Jul 21, 2026

3 Cash-Burning Stocks with Open Questions

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By